Business Context and Reporting Period
Company: vTv Therapeutics Inc. (VTVT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: vTv is a late-stage biopharmaceutical company focused on developing oral therapies for metabolic and inflammatory diseases. Its lead asset is cadisegliatin (TTP399), a liver-selective glucokinase activator in Phase 3 trials for Type 1 Diabetes (T1D). The company also maintains a pipeline including TTP273 (GLP-1 RA), HPP737 (PDE4 inhibitor), and Nrf2/Bach1 modulators.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $1,017 |
| Net Loss (Attributable to vTv) | $(26,974) | $(18,462) |
| Research & Development Expenses | $17,861 | $11,546 |
| General & Administrative Expenses | $14,947 | $13,651 |
| Cash and Cash Equivalents (Year End) | $88,932 | $36,746 |
| Accumulated Deficit | $(326,692) | $(299,718) |
| Net Cash Used in Operating Activities | $(25,255) | $(25,307) |
| Net Cash Provided by Financing Activities | $77,441 | $52,607 |
Note: The company has no debt obligations listed on the balance sheet as of December 31, 2025. Liquidity is supported by cash reserves and equity financing.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $0 in 2025 from $1.0 million in 2024. The 2024 revenue was driven by a development milestone under the Newsoara License Agreement and deferred revenue recognition from a terminated Huadong agreement.
- Increased Operating Loss: Net loss attributable to vTv increased by approximately 46% (from $18.5M to $27.0M) due to higher R&D spending.
- R&D Expense Surge: R&D expenses rose 55% to $17.9 million, primarily driven by a $5.4 million increase in cadisegliatin clinical study costs and a $1.0 million milestone payment to Novo Nordisk for initiating the Phase 3 trial.
- Capital Raise: In September 2025, the company completed a private placement raising approximately $80.0 million in gross proceeds, significantly boosting cash reserves from $36.7 million to $88.9 million.
- Regulatory Status: The FDA lifted a clinical hold on the cadisegliatin program in March 2025 after the company demonstrated that a previously uncharacterized signal was an experimental artifact.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Clinical Progress: The CATT1 Phase 3 trial for cadisegliatin in T1D resumed in Q2 2025. Enrollment is ongoing, with completion expected in Q3 2026.
- New Partnerships: In December 2025, a Phase 2 trial for cadisegliatin in Type 2 Diabetes was initiated in the Middle East with partner G42 Investments. In January 2026 (subsequent event), the company received a $20.0 million upfront payment from Newsoara for global rights to HPP737.
- Liquidity: Management expects current cash resources, combined with the $20M Newsoara payment, to fund operations beyond the anticipated topline data readout from the CATT1 trial.
Risks and Contingencies
- Development Risk: Success depends entirely on the outcome of the CATT1 Phase 3 trial. Failure to meet primary endpoints (reduction in hypoglycemia) would materially harm the business.
- Capital Needs: The company anticipates continued losses and will require additional capital to complete development and commercialization. Future financing may result in significant dilution.
- Regulatory Uncertainty: While the clinical hold was lifted, future regulatory reviews remain uncertain. The company has no products approved for commercial sale.
- Concentration of Ownership: Significant investors (MacAndrews & Forbes and Private Placement Investors) hold substantial voting power, which may influence corporate decisions.
Key Facts for Investor Verification
- Cash Runway: Verify if the $88.9M cash balance plus the $20M Newsoara upfront payment is sufficient to reach the CATT1 topline data readout without further dilution.
- CATT1 Enrollment: Monitor the pace of patient enrollment in the CATT1 Phase 3 trial to ensure the Q3 2026 completion target remains realistic.
- Warrant Liability: Review the fair value changes of the significant number of warrants issued in the 2025 Private Placement (approx. 5.2M common warrants and 4.6M pre-funded warrants) and their impact on future earnings.
- Intellectual Property: Confirm the status of the patent portfolio for cadisegliatin, with key patents expiring between 2031 and 2041.
- Subsequent Events: Note the January 2026 amendment with Newsoara, which expanded rights to HPP737 globally for a $20M upfront payment, providing immediate liquidity.